Glenmark’s Ryaltris Gains US FDA Approval for Kids Aged 6‑12

Glenmark Pharma announced on Thursday that the US Food and Drug Administration has given the nod to broaden the age range of its anti‑allergy nasal spray, Ryaltris. Until now the product was approved only for adults and adolescents 12 years and older; the new approval means kids as young as six can now be treated with the same once‑daily spray.

Ryaltris combines two well‑known agents – azelastine, an antihistamine, and fluticasone, a corticosteroid – to tackle the twin culprits of sneezing, runny nose and itchy eyes that accompany seasonal allergic rhinitis. The FDA’s decision was based on data from a recent pediatric trial that showed the medication is both safe and effective in the younger age group.

“We are thrilled that the agency has recognized the benefit of Ryaltris for children,” said Viswanath Pilla, Managing Director – Global Business Development at Glenmark. He added that the expansion will "significantly expand our addressable market in the United States and bring relief to many families dealing with pollen‑related symptoms during spring and summer."

Allergy season, especially pollen‑driven rhinitis, is a common complaint among school‑age children in the United States. According to the American Academy of Allergy, Asthma & Immunology, up to 30 % of children suffer from some form of allergic rhinitis, which can affect school performance and quality of life. A convenient, once‑daily spray that works quickly is a welcome addition to the therapeutic armamentarium.

From a commercial perspective, the widened indication could boost Glenmark’s US revenue streams. The company, which has been eyeing growth in the specialty‑medicine space, now has a product that can be marketed to a broader pediatric population, potentially adding several hundred million dollars to its pipeline over the next few years.

Analysts have taken note. Several brokerage houses upgraded their outlook on Glenmark, citing the FDA approval as a catalyst for higher sales and improved market penetration in North America. The move also underscores the firm’s strategy of leveraging existing assets for new indications – a path that often yields faster returns than developing brand‑new molecules.

While the approval is a major win, Glenmark will still need to navigate the usual post‑marketing surveillance and ensure that physicians are educated about the proper use of the spray in children. Training programs and real‑world evidence collection are expected to roll out in the coming months.

In short, the FDA’s green light not only brings a proven allergy solution to younger patients but also positions Glenmark as a stronger player in the competitive US allergy‑treatment market.